Iambic Therapeutics, Inc. Sample Contracts
Confirmatory Executive Offer Letter September 18, 2026Confirmatory Executive Offer Letter • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances)
This letter agreement (the “Agreement”) is entered into between Iambic Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the effective date of the first registration statement that is filed by the Company and declared effective pursuant to Section 12(b) of the Exchange Act with respect to the Company’s common stock (the “Effective Date”). The purpose of this Agreement is to confirm the terms and conditions of your continued employment with the Company as of the Effective Date.
RESEARCH COLLABORATION AND LICENSE AGREEMENT DATED AS OF FEBRUARY 3, 2026 BY AND BETWEEN IAMBIC THERAPEUTICS, INC. AND TAKEDA PHARMACEUTICALS, U.S.A., INC.Research Collaboration and License Agreement • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration and License Agreement (this “Agreement”), effective as of February 3, 2026 (the “Effective Date”), is entered into by and between Takeda Pharmaceuticals U.S.A., Inc., a corporation organized under the laws of the State of Delaware (“Takeda”), and Iambic Therapeutics, Inc., a Delaware corporation having a place of business at 5627 Oberlin Drive, Suite 120, San Diego, California, 92121 (“Iambic”). Takeda and Iambic are referred to individually as a “Party” and collectively as the “Parties.”
IAMBIC THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 1, 2026, by and among Iambic Therapeutics, Inc., a Delaware corporation (the “Company”), the Key Holders (as defined below), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
Collaboration and Option AgreementCollaboration and Option Agreement • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This COLLABORATION AND OPTION AGREEMENT (the “Agreement”) is entered into as of September 23, 2024 (the “Effective Date”) between Iambic Therapeutics, Inc., a Delaware corporation, having its principal place of business at 5627 Oberlin Drive, Suite 120, San Diego, California 92121 (“Iambic”) and H. Lundbeck A/S, a Danish corporation, having its principal place of business at Ottiliavej 9, 2500 Valby, Denmark (“Lundbeck”). Lundbeck and Iambic each may be referred to herein individually as a “Party” or collectively as the “Parties.” All attached appendices, exhibits and schedules are a part of this Agreement.
IAMBIC THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Iambic Therapeutics, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
ContractWarrant Agreement • July 24th, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.
ContractCollaboration and Option to License Agreement • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
[***] Certain information in this document has been omitted from this exhibit pursuant to Item 601(b) of Regulation S-K because it is both not material and is the type that the Registrant treats as private or confidential.
ContractWarrant to Purchase Stock • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.
EMPLOYMENT AGREEMENTEmployment Agreement • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
This Employment Agreement (“Agreement”) is made on and effective as of the date signed by the last party to sign on the signature page below.
LEASE by and between BRE-BMR OBERLIN LP, a Delaware limited partnership and IAMBIC THERAPEUTICS, INC., a Delaware corporationLease Agreement • September 21st, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS LEASE (this “Lease”) is entered into as of this 24th day of July, 2023 (the “Execution Date”), by and between BRE-BMR OBERLIN LP, a Delaware limited partnership (“Landlord”), and IAMBIC THERAPEUTICS, INC., a Delaware corporation (“Tenant”).